[show abstract][hide abstract] ABSTRACT: Vasomotor nephropathy is a common renal dysfunction in very preterm neonates.
To determine whether theophylline could prevent vasomotor nephropathy in very preterm infants with respiratory distress syndrome.
A randomised, double blind, placebo controlled trial of 50 preterm infants of gestational age < or = 32 weeks needing assisted ventilation. Infants received an intravenous dose of theophylline (1 mg/kg) or placebo for three days. The 24 hour urine volume was measured daily. On days 2, 5, and 11, blood samples and 12 hour urine collections were analysed for electrolytes, creatinine, and urea.
On day 1, urine output was significantly higher in the theophylline (2.4 (0.9) ml/kg/h) than the placebo (1.6 (1.0) ml/kg/h; p = 0.023) group (values are mean (SD)). The incidence of oligoanuria was significantly lower in the theophylline treated (5%) than the placebo (33%) group. Twenty four hours after the first administration of theophylline/placebo, serum creatinine concentration was significantly lower in the theophylline (0.76 (0.23) mg/dl) than the placebo (1.0 (0.41) mg/dl; p = 0.025) group. On day 5 an increase in serum creatinine was observed in both groups. On day 11 a significant reduction in serum creatinine was observed, compared with day 5, with no difference between the two groups.
The results suggest that, in very preterm infants with respiratory distress syndrome, early theophylline administration improves renal function during the first two days of life.
Archives of Disease in Childhood - Fetal and Neonatal Edition 03/2006; 91(2):F80-4. · 3.45 Impact Factor
[show abstract][hide abstract] ABSTRACT: We retrospectively analyzed the outcome of hematopoietic stem cell transplantations (HSCT) performed at our Center between 1991 and 2002 in 11 unselected patients with Omenn syndrome, a variant of severe combined immunodeficiency. The patients' mean age at the time of the first HSCT was 8.4 months. Two patients received two, and one patient three, HSCT procedures. The resulting 15 HSCT derived in seven cases from HLA-haploidentical parents, in four patients from matched unrelated donors, in three cases from an HLA phenotypically identical related donor, and in one case from an HLA genotypically identical family donor. Nine out of 11 patients are alive and immunoreconstituted 30-146 months after transplantation. At the time of the most recent evaluation, all of the nine survivors had normal T-cell function, and eight of them had developed normal antibody production. This study demonstrates an overall mortality of 18.2%, which is substantially lower than previously reported. Early recognition of OS, rapid initiation of adequate supportive treatment and HSCT lead to improved outcome for this otherwise fatal disease, regardless of the origin and matching of hematopoietic stem cells.
Bone Marrow Transplantation 08/2005; 36(2):107-14. · 3.54 Impact Factor
[show abstract][hide abstract] ABSTRACT: Summary 35, respectively 36 patients undergoing colorectal surgery received perioperative prophylaxis with 200 mg ciprofloxacin i.v. 12-hourly for one day (group I) or with 2 g cefazolin i.v. 12-hourly for three days (group II). Additionally all patients received 500 mg metronidazole eight-hourly for one day. 34, respectively 36 patients could be evaluated. One patient had to be excluded because he developed swelling of the forearm immediately after start of the ciprofloxacin infusion so that the drug was stopped and the patient was treated with cefazolin. He was evaluable for tolerability but not for efficacy. In group I, three patients developed complications in wound healing, two of them with infections; in group II the respective figures were five with three infections. Both regimens can be recommended for perioperative use to prevent bacterial infections, ciprofloxacin having the advantage of low dose (2 × 200 mg) and short duration of treatment (one day).